FDA Approves Imlunestrant for Breast Cancer Treatment
Here’s a breakdown of the key information from the provided text regarding imlunestrant (Inluriyo) for metastatic breast cancer:
What is it?
* imlunestrant (Inluriyo) is a new oral therapy for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
Why is it important?
* It offers a “meaningful alternative treatment option” due to its efficacy, tolerability, adn oral governance.
* It expands the treatment landscape for patients with the ESR1 mutation, providing them with more choices.
* it offers potential for “flexibility in their daily lives and disease management” and “renewed hope.”
how effective/safe is it?
* Adverse Events (aes):
* Grade 3 or higher AEs occurred in 17.1% of patients on imlunestrant, 20.7% on endocrine therapy, and 48.6% on imlunestrant plus abemaciclib.
* Most AEs with imlunestrant were low grade.
* Common AEs included lab abnormalities, musculoskeletal pain, fatigue, diarrhea, nausea, constipation, and abdominal pain.
* Only 4.6% of patients discontinued treatment due to AEs.
* dose reductions were needed in 2.4% of patients, and dose interruptions in 10%.
Source:
* The information comes from a news release by Lilly, announcing FDA approval on september 25, 2025.